Search Medical Condition
Please enter condition
Please choose location from dropdown

Stanford, California Clinical Trials

A listing of Stanford, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (961) clinical trials

CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS&AL

Primary Objective: To determine the rate of graft versus host disease (GvHD) free, relapse free survival (GRFS) at one year following CD34 selected allogeneic hematopoietic cell transplantation using myeloablative conditioning combined with an infusion of phenotypic CD8+ memory T cells from human leukocyte antigen (HLA) matched donors for patients with …

Phase

0.0 miles

Learn More »

Product Surveillance Registry

The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge …

Phase N/A

5.72 miles

Learn More »

Evaluation of the GORE TAG Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta (Zone 0/1)

The objective of this study is to determine whether the GORE TAG Thoracic Branch Endoprosthesis is safe and effective in treating lesions of the aortic arch and descending thoracic aorta.

Phase N/A

314.3 miles

Learn More »

Evaluation of the GORE TAG Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta (Zone 2)

The objective of this study is to determine whether the GORE TAG Thoracic Branch Endoprosthesis is safe and effective in treating lesions of the aortic arch and descending thoracic aorta.

Phase N/A

314.35 miles

Learn More »

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

The objective is to demonstrate the non-inferiority of edoxaban to standard of care (SOC; including low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors) in the treatment and secondary prevention of VTE in pediatric subjects with regard to the composite efficacy endpoint (ie, symptomatic …

Phase

315.83 miles

Learn More »

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

The purpose of this study is to evaluate the effect of perhexiline on exercise performance (efficacy) and safety in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure following dosing for 16 weeks.

Phase

1759.48 miles

Learn More »

3T MRI CIED Post-Approval Study

The purpose of this study is to evaluate product performance of Magnetic Resonance (MR) Conditional Cardiac Implantable Electronic Devices (CIED) following 3 tesla (3T) MRI exposure. This will be achieved by evaluating the changes in pacing capture threshold (PCT) measurements following 3T MRI scan exposure. This study is required by …

Phase N/A

5.72 miles

Learn More »

Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth

The primary goals of this proposal are to investigate the etiological mechanisms associated with antidepressant-related dysfunctional emotional arousal and to characterize baseline neurobiological risk factors that predict the development of dysfunctional emotional arousal in treatment seeking youth with a family history of BD. Antidepressants have moderate benefit for treating mood …

Phase N/A

2031.08 miles

Learn More »

TrialNet Pathway to Prevention of T1D

Detailed Description: The Pathway to Prevention Study is conducted in two parts: Screening Monitoring (annual and semi-annual depending on risk) In Screening , a simple blood test is done to screen for the presence of diabetes-related biochemical autoantibodies (GAD and mIAA). Additional autoantibodies ICA, IA-2A, and ZnT8A will also measured …

Phase N/A

28.39 miles

Learn More »

Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes

There is evidence that early, intensive diabetes management may preserve C-peptide secretion possibly by allowing decreased islet cell activity or "islet cell rest". Less metabolically active islet cells result in a decreased inflammatory response and decreased autoantigen expression. This leads to a decrease in the destruction of beta cells and …

Phase

947.95 miles

Learn More »